Phosphogliv powder lyophilisate injection vial 2.5 g N5
Condition: New product
1000 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Glycyrrhizic acid + Phospholipids
Release form
Solution
Composition
Active ingredient: Glycyrrhizic acid + Phospholipids (Glycyrrhizic acid + Phospholipides) Active ingredient concentration (mg): Phospholipids (lipoid C100) 500 mg, sodium glycyrrhizinate (trisodium glycyrrhizic acid) 200 mg
Pharmacological effect
Combined preparation. It exerts membrane stabilizing, hepatoprotective and antiviral effects. Phosphatidylcholine (the main component of phospholipids) is the main structural element of cellular and intracellular membranes, capable of restoring their structure and function when damaged, exerting a cytoprotective effect. Normalizes protein and lipid exchanges, prevents the loss of hepatocytes enzymes and other active substances, restores liver detoxifying function, inhibits the formation of connective tissue, reducing the risk of fibrosis and cirrhosis. Glycyrrhizic acid has anti-inflammatory effect, inhibits viral reproduction in the liver and other organs due to stimulation production of interferons, increasing phagocytosis, increasing the activity of natural killer cells. It has a hepatoprotective effect due to antioxidant and membrane stabilizing activity. Potentiates the action of endogenous glucocorticoids, providing an anti-inflammatory and antiallergic effect in non-infectious lesions of the liver. In skin lesions due to the membrane-stabilizing and anti-inflammatory action of the components limits the spread of the process and contributes to the regression of the disease.
Indications
Fatty degeneration of the liver (hepatosis), alcoholic, toxic, including medicinal, liver damage; As part of complex therapy of viral hepatitis (acute and chronic), cirrhosis of the liver and psoriasis.
Contraindications
Hypersensitivity to glycyrrhizic acid, phosphatidylcholine or other components of the drug; Antiphospholipid syndrome; Pregnancy (data on efficacy and safety is not enough); Breastfeeding period (data on efficacy and safety is not enough); Children's age under 12 years of age (data on efficacy and safety not enough).
Use during pregnancy and lactation
The drug is contraindicated for use during pregnancy and lactation (breastfeeding).
Dosage and administration
Adults and children over 12 years: in / in, after dissolving the powder in 10 ml of water for injection. In / in the introduction should be slow. 10 ml is administered daily, 2 times a day, in the morning and in the evening for 10 days, followed by a switch to oral administration of the drug in the form of capsules. The duration of the course can be increased according to the recommendation of the doctor.
Side effects
On the part of the skin and subcutaneous tissues: at increased individual sensitivity, a skin rash may appear, which disappears after discontinuation of the drug. If the daily dose is exceeded: sodium and fluid retention are possible, edema, increased blood pressure, hypokalemia. When these symptoms appear, depending on their severity, it is necessary to reduce the dose of the drug and / or prescribe spironolactone at 50-100 mg / day.
Interaction with other drugs
The contents of the vial should not be mixed with other solutions. To dissolve, use only water for injection. It is forbidden to use physiological sodium chloride solution or glucose solution to dilute the drug.